HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: Vorinostat (also known as SAHA; suberoylanilide hydroxamic acid), a pan-HDAC inhibitor, is currently used in the clinic to treat cutaneous T cell lymphoma (CTCL).